West Pharmaceutical Services (WST) Assets Average (2010 - 2026)

West Pharmaceutical Services (WST) has reported Assets Average for 17 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

• Quarterly Assets Average rose 8.13% year-over-year to $4.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.1 billion (up 8.13% YoY) and the FY2025 annual result came in at $4.0 billion, up 5.89% from the prior year.
• Assets Average fell to $4.1 billion in Q2 2026 per WST's latest filing, from $4.2 billion in the prior quarter.
• Over the last five years, Assets Average for WST reached as high as $4.2 billion in Q1 2026 and fell as low as $3.3 billion in Q1 2022.
• A 5-year average of $3.7 billion and a median of $3.7 billion in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average rose 19.43% — and 2024, when it decreased 4.08%.
• Year by year, Assets Average stood at $3.5 billion in 2022, then increased by 9.38% to $3.8 billion in 2023, then decreased by 3.5% to $3.7 billion in 2024, then gained by 14.45% to $4.2 billion in 2025, then dropped by 2.26% to $4.1 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $4.1 billion, $4.2 billion, and $4.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.